Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN),…
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,…
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the…
Unisys Innovation Program Announces the Winners of Its 16th Annual Competition
Top three teams recognized for ideas to create sustainable electric mobility, tumor…
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
The TUXEDO-3 trial is the first study to evaluate the intracranial and…
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to…